Biolidics selling 27.5 mil new shares at 28 cents each in conjunction with Catalist listing

PC Lee
PC Lee12/11/2018 06:23 PM GMT+08  • 2 min read
Biolidics selling 27.5 mil new shares at 28 cents each in conjunction with Catalist listing
SINGAPORE (Dec 11): Medtech company Biolidics is selling 27.5 million new shares at 28 cents each to retail and institutional investors in a private placement ahead of its listing on the Catalist Board of the Singapore Exchange.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Dec 11): Medtech company Biolidics is selling 27.5 million new shares at 28 cents each to retail and institutional investors in a private placement ahead of its listing on the Catalist Board of the Singapore Exchange.


See: Clearbridge Health associate Biolidics lodges prelim prospectus

Incorporated in 2009, Singapore-based Biolidics is a medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring. Biolidics has developed the ClearCell FX1 System, a fully automated IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.